Skip to main content

A Phase 1/2 Study Evaluating the Safety and Efficacy of IOV-2001 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Iovance Biotherapeutics, Inc

Start Date

October 26, 2021

End Date

October 31, 2026
 

Administered By

Duke Cancer Institute

Awarded By

Iovance Biotherapeutics, Inc

Start Date

October 26, 2021

End Date

October 31, 2026